PRESS RELEASE

Q4 2022 — Press release

Q4 2022PDF · 6 pages90 KB
January 24, 2023
3M Reports Fourth-Quarter and Full-Year
2022 Results
ST. PAUL, Minn., Jan. 24, 2023 /PRNewswire/ -- 3M (NYSE: MMM) today reported fourth-
quarter and full-year 2022 results and provided its 2023 financial outlook.
"3M continues to focus on delivering for customers and shareholders in a challenging
economic environment," said 3M chairman and CEO Mike Roman. "We posted organic
growth of 0.4 percent -- versus our expectation of 1 to 3 percent -- adjusted margins of 19.1
percent, and adjusted earnings of $2.28 per share. The slower-than-expected growth was
due to rapid declines in consumer-facing markets – a dynamic that accelerated in December
– along with significant slowing in China due to COVID-related disruptions. As demand
weakened, we adjusted manufacturing output and controlled costs, which enabled us to
improve inventory levels.
"In a year impacted by inflation, global conflicts, and economic softening, our team took
actions to position 3M for future success," said Roman. "We managed our portfolio –
including the divestiture of our Food Safety business, planned spin-off of our Health Care
business, and commitment to exit PFAS manufacturing by the end of 2025 – while
continuing to work towards a mediated resolution for Combat Arms litigation. We invested in
growth and productivity, while following through on sustainability commitments.
"We expect macroeconomic challenges to persist in 2023," Roman continued. "Our focus is
executing the actions we initiated in 2022 and delivering the best performance for customers
and shareholders. Based on what we see in our end markets, we will reduce approximately
2,500 global manufacturing roles – a necessary decision to align with adjusted production
volumes."
Fourth-Quarter Highlights:
Company reports GAAP earnings per share of $0.98, which included a $1.15 per share
pre-tax charge relating to PFAS manufacturing exit costs adjusted for in special items.
Adjusted earnings per share of $2.28, excluding the impact of special items.
Q4 2022 	Q4 2021
GAAP EPS 	$ 	0.98 	$ 	2.31
Special Items 	1.30 	0.14
Adjusted EPS 	$ 	2.28 	$ 	2.45
Memo:
GAAP operating income margin 	7.8 % 	18.8 %
Adjusted operating income margin 	19.1 % 	20.0 %
See the "Supplemental Financial Information Non-GAAP Measures" section for applicable
information.

-- 1 of 6 --

Sales of $8.1 billion, down 6 percent year-on-year, which included impacts of negative
2 percent from divestitures and negative 5 percent from foreign currency translation
due to strength of U.S. dollar.
Organic sales growth of 0.4 percent year-on-year which included a 2.6 percentage
point headwind from the decline in disposable respirator demand, along with the exit of
Russia.
Operating cash flow was $1.9 billion, down 4 percent year-on-year, while adjusted free
cash flow was $1.7 billion, up 3 percent year-on-year.
3M returned $1.4 billion to shareholders via dividends and gross share repurchases.
Full-Year Highlights:
Full Year 2022 	Full Year 2021
GAAP EPS 	$ 	10.18 	$ 	10.12
Special Items 	(0.08) 	0.61
Adjusted EPS 	$ 	10.10 	$ 	10.73
Memo:
GAAP operating income margin 	19.1 % 	20.8 %
Adjusted operating income margin 	20.8 % 	22.2 %
See the "Supplemental Financial Information Non-GAAP Measures" section for applicable
information.
Sales of $34.2 billion, down 3 percent year-on-year, which included impacts of
negative 1 percent from divestitures and negative 4 percent from foreign currency
translation due to strength of U.S. dollar.
Organic sales growth of 1.2 percent year-on-year which included a 2.0 percentage
point headwind from the decline in disposable respirator demand, along with the exit of
Russia.
GAAP earnings per share of $10.18, up 1 percent, while adjusted earnings per share
was $10.10, down 6 percent. Earnings reflect year-on-year changes in special items,
headwinds from manufacturing productivity, increased raw materials/logistics costs,
investments, and negative foreign exchange impacts. Benefits to earnings included
selling price actions, strong spending discipline, and lower shares outstanding.
Operating cash flow was $5.6 billion, down 25 percent year-on-year, while adjusted
free cash flow was $4.7 billion, down 25 percent year-on-year. The declines were
primarily due to lower net income and the cash impact from capitalization of R&D for
U.S. tax purposes.
3M returned $4.8 billion to shareholders via dividends and gross share repurchases.
Received approximately $1 billion in consideration and reduced outstanding shares by
16 million via exchange offer due to Food Safety divestiture.
2022 Results Based on New 2023 Outlook Basis
In December 2022, 3M announced it will exit per- and polyfluoroalkyl substance (PFAS)
manufacturing by the end of 2025. Beginning in 2023, 3M expects to adjust for the results of
these manufactured PFAS products in arriving at non-GAAP results. This expands the
current adjustment for special items in 3M's non-GAAP results to include the sales and
estimates of income, exit costs, and associated activity of PFAS manufacturing.

-- 2 of 6 --

Comparable 2022 GAAP sales, earnings, and cash flow amounts are provided in the
highlights section above. For additional clarity, the impact of further adjusting for 2022 PFAS
manufacturing sales of $1.4 billion, estimated income of $0.22 per share and related activity
on certain non-GAAP amounts on the existing versus new 2023 outlook basis is presented
below:
Full Year 2022 — Certain non-GAAP Amounts
(Dollars in millions, except per share amounts) 	Existing Basis 	New Outlook Basis
Adjusted total sales growth 	(3.2) % 	(3.6) %
Adjusted organic sales growth 	1.2 % 	0.8 %
Adjusted earnings per share 	$ 	10.10 	$ 	9.88
Adjusted operating cash flow 	$ 	6,440 	$ 	6,404
Adjusted free cash flow conversion 	82 % 	86 %
See the "Supplemental Financial Information Non-GAAP Measures — New Outlook Basis"
section for further information regarding this change.
Full-Year 2023 Outlook
3M's full-year expectations for 2023 include the following:
-6 to -2 percent adjusted total sales growth^ reflecting the following:
-3 percent to flat adjusted organic sales growth^, includes -2 percentage point
impact from disposable respirator decline and exit of Russia
-2 to -1 percent adjusted foreign currency translation impact^
-1 percent adjusted divestiture impact^
Adjusted earnings per share^ of $8.50 to $9.00, versus 2022 of $9.88 on a comparable
basis
2023 adjusted earnings per share include -$0.55 to -$0.80 of combined year-on-
year headwinds from the decline in disposable respirator demand, exit of Russia,
foreign currency translation, and divestitures
Adjusted operating cash flow^ of $5.8 to $6.3 billion contributing to 90% to 100%
adjusted free cash flow conversion^
These expectations reflect changes in certain of 3M's non-GAAP measures beginning in
2023 as discussed in the preceding section.
3M expects to record a pre-tax restructuring charge of $75 to $100 million in the first quarter
of 2023. This pre-tax charge and associated savings is included in the company's full-year
2023 outlook.
^ As further discussed at * within the "Supplemental Financial Information Non-GAAP
Measures — New Outlook Basis" section, 3M cannot, without unreasonable effort, forecast
certain items required to develop meaningful comparable GAAP financial measures and,
therefore, does not provide them on a forward-looking basis reflecting these items.
Conference Call
3M will conduct an investor teleconference at 9 a.m. EST (8 a.m. CST) today. Investors can
access this conference via the following:

-- 3 of 6 --

Live webcast at http://investors.3M.com.
Live telephone:
Call 800-762-2596 within the U.S. or +1 212-231-2916 outside the U.S. Please join the
call at least 10 minutes before the start time.
Webcast replay:
Go to 3M's Investor Relations website athttp://investors.3M.com and click on
"Quarterly Earnings."
Telephone replay:
Call 800-633-8284 within the U.S. or +1 402-977-9140 outside the U.S. (for both U.S.
and outside the U.S., the access code is 22024173). The telephone replay will be
available until 11:30 a.m. EST (10:30 a.m. CST) on January 31, 2023.
Consolidated Financial Statements and Supplemental Financial Information Non-
GAAP Measures
View the Consolidated Financial Statements and Supplemental Financial Information Non-
GAAP Measures on 3M's website:
https://investors.3m.com/Financial-Statements-Q422
Forward-Looking Statements
This news release contains forward-looking information about 3M's financial results and
estimates and business prospects that involve substantial risks and uncertainties. You can
identify these statements by the use of words such as "anticipate," "estimate," "expect,"
"aim," "project," "intend," "plan," "believe," "will," "should," "could," "target," "forecast" and
other words and terms of similar meaning in connection with any discussion of future
operating or financial performance or business plans or prospects. Among the factors that
could cause actual results to differ materially are the following: (1) worldwide economic,
political, regulatory, international trade, geopolitical, capital markets and other external
conditions and other factors beyond the Company's control, including inflation, recession,
military conflicts, natural and other disasters or climate change affecting the operations of
the Company or its customers and suppliers; (2) risks related to unexpected events such as
the public health crises associated with the coronavirus (COVID-19) global pandemic; (3)
foreign currency exchange rates and fluctuations in those rates; (4) liabilities related to
certain fluorochemicals, including lawsuits concerning various PFAS-related products and
chemistries, and claims and governmental regulatory proceedings and inquiries related to
PFAS in a variety of jurisdictions; (5) legal proceedings, including significant developments
that could occur in the legal and regulatory proceedings described in the Company's Annual
Report on Form 10-K for the year ended Dec. 31, 2021, as updated by the Company's
Current Report on Form 8-K dated April 26, 2022, and any subsequent quarterly reports on
Form 10-Q (the "Reports"); (6) competitive conditions and customer preferences; (7) the
timing and market acceptance of new product and service offerings; (8) the availability and
cost of purchased components, compounds, raw materials and energy due to shortages,
increased demand and wages or supply chain interruptions; (9) unanticipated problems or
delays with the phased implementation of a global enterprise resource planning (ERP)
system, or security breaches and other disruptions to the Company's information technology
infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and other
strategic events resulting from portfolio management actions and other evolving business
strategies, and possible organizational restructuring; (11) operational execution, including
scenarios where the Company generates fewer productivity improvements than planned;

-- 4 of 6 --

(12) financial market risks that may affect the Company's funding obligations under defined
benefit pension and postretirement plans; (13) the Company's credit ratings and its cost of
capital; (14) tax-related external conditions, including changes in tax rates, laws or
regulations; (15) matters relating to the proposed spin-off of the Company's Health Care
business, including whether the transaction will be completed, or if completed, will be on the
expected terms; the risk that the expected benefits will not be realized; the risk that the costs
or dis-synergies will exceed the anticipated amounts; the ability to satisfy the various closing
conditions; potential business disruption; the diversion of management time; the impact of
the transaction (or its pendency) on the Company's ability to retain talent; potential impacts
on the Company's relationships with its customers, suppliers, employees, regulators and
other counterparties; the ability to realize the desired tax treatment (including whether an
Internal Revenue Service private letter ruling will be sought or obtained); the risk that any
consents or approvals required will not be obtained; risks associated with financings that
may be undertaken and indebtedness that may be incurred in connection with the
transaction; (16) matters relating to the voluntary chapter 11 proceedings of the Company's
subsidiary Aearo Technologies and certain of its affiliates (the "Aearo Entities"), including
legal risks related to the chapter 11 proceedings; potential impacts to the Company's
reputation and its relationships with customers, suppliers, employees, regulators and other
counterparties and community members; potential impacts to the Company's liquidity or
results of operations, including risks related to the amount that will be necessary to fully and
finally resolve all of the Company's obligations to make payments to resolve such claims
under the terms of its funding and indemnification agreement with the Aearo Entities; and the
Aearo Entities' ability to navigate the chapter 11 proceedings to obtain approval and
consummation of a plan of reorganization; and (17) matters relating to the Company's plans
to exit PFAS manufacturing and discontinue use of PFAS across its product portfolio (the
"exit"), including the actual timing, costs and financial impact of such exit; the Company's
ability to complete such exit, on the anticipated timing or at all; potential governmental or
regulatory actions relating to PFAS manufacturing and production, or the Company's exit
plans; the Company's ability to identify and manufacture acceptable substitutes for the
discontinued products, and the possibility that such substitutes will not achieve the
anticipated or desired commercial or operational results; potential litigation relating to the
Company's exit plans; and the possibility that the planned exit will involve greater costs than
anticipated, or otherwise have negative impacts on the Company's relationships with its
customers and other counterparties. Changes in such assumptions or factors could produce
significantly different results. A further description of these factors is located in the Reports
under "Cautionary Note Concerning Factors That May Affect Future Results" and "Risk
Factors" in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A
(Quarterly Reports). The Company assumes no obligation to update any forward-looking
statements discussed herein as a result of new information or future events or
developments.
About 3M
3M (NYSE: MMM) believes science helps create a brighter world for everyone. By unlocking
the power of people, ideas and science to reimagine what's possible, our global team
uniquely addresses the opportunities and challenges of our customers, communities, and
planet. Learn how we're working to improve lives and make what's next at 3M.com/news or
on Twitter at @3M or @3MNews.

-- 5 of 6 --

Please note that the company announces material financial, business and operational
information using the 3M investor relations website, SEC filings, press releases, public
conference calls and webcasts. The company also uses the 3M news center and social
media to communicate with our customers and the public about the company, products and
services and other matters. It is possible that the information 3M posts on the news center
and social media could be deemed to be material information. Therefore, the company
encourages investors, the media and others interested in 3M to review the information
posted on 3M's news center and the social media channels such as Twitter @3M or
@3MNews.
Contacts
3M
Investor Contacts:
Bruce Jermeland, 651-733-1807
or
Diane Farrow, 612-202-2449
or
Media contact:
Tim Post, tpost3@mmm.com
View original content to download multimedia:https://www.prnewswire.com/news-
releases/3m-reports-fourth-quarter-and-full-year-2022-results-301728788.html
SOURCE 3M

-- 6 of 6 --